AdVTMM2-transduced dendritic cell vaccine

AXP000166.1 · Cancer vaccine

Platform
autologous dendritic cells transduced ex vivo with an adenoviral vector
Originator
University of Pittsburgh
Sponsor
University of Pittsburgh

Names

NameTypeSource
AdVTMM2-transduced dendritic cell vaccinepreferred namecurator
AdVTMM2codencit
AdVTMM2-transduced Dendritic Cell Vaccinesynonymncit

Virus

Role
Ex vivo gene transfer
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
non replicating
Modifications
non-replicating adenoviral vector encoding tyrosinase, MART-1 and MAGE-A6; used to transduce autologous dendritic cells ex vivo
Transgenes
TYR, MLANA, MAGEA6
Route
ex vivo
Carrier
autologous dendritic cells
Source
evidence

Cross-references

NCI Thesaurus
C102753

Approvals

No regulatory approval recorded.

Clinical trials (0)

No trial in the latest ClinicalTrials.gov snapshot names this program.

Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT01622933Multiple Antigen-Engineered DC Vaccine for MelanomaCompletedPhase 12012-062016-0535Melanomaname in intervention: AdVTMM2

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 22737604Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.Oncoimmunology2012name in abstract: AdVTMM2

NIH grants

ProjectTitleOrganisationPIYearsLinked by
P50CA121973Biospecimen Core/Immunologic Monitoring and Cellular Products LaboratoryUNIVERSITY OF PITTSBURGH AT PITTSBURGHBUTTERFIELD, LISA HELENE2013–2017name in abstract: AdVTMM2-transduced dendritic cell vaccine

Notes

Autologous dendritic cells transduced outside the body with an adenovirus encoding tyrosinase, MART-1 and MAGE-A6 (AdVTMM2), then given back to the patient; phase 1 in melanoma. Entered as ex vivo gene transfer: the adenovirus modifies the cells rather than being administered itself.

How to cite

AdVTMM2-transduced dendritic cell vaccine (AXP000166.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000166.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.